In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Mast Therapeutics, Inc.

http://www.masttherapeutics.com/

Latest From Mast Therapeutics, Inc.

Deal Watch: RedHill Finds New Partner For Movantik

Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.

Deals Business Strategies

Ligand Adds New Expertise, Revenue Potential With Pfenex Buyout

Deal Snapshot: In acquiring its fellow San Diego firm for an estimated deal value of up to $516m, Ligand picks up protein-expression technology, revenue-driving partnerships and the potential for more.

Deals M & A

Ligand Snaps Up Pfenex For Half A Billion

Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.

Deals Biosimilars

Clock Ticks On Pfenex Teriparatide Equivalence Windfall

Pfenex has less than two months for an “A” designation for therapeutic equivalence for to be granted for its Bonsity (teriparatide) 505(b)(2) product by the US FDA if it wishes to realize maximum value under the companies’ partnership agreement with Alvogen.

Generic Drugs FDA
See All

Company Information

  • Other Names / Subsidiaries
    • Adventrx Pharmaceuticals, Inc.
    • Aires Pharmaceuticals, Inc.
    • SynthRx, Inc.
UsernamePublicRestriction

Register